Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.

Company AnnouncementNet sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...

Blood cancer patients in their 40s and 50s are urging Pharmac to overhaul its funding model, saying they have potentially ...

(Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The Phase II cut in Alzheimer’s puts a question mark against the lofty heights J&J had envisaged for seltorexant. Less than a ...

Looking back, I realise there were all sorts of symptoms there. But after I went skiing, I felt I was having a heart attack" ...

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...